Literature DB >> 3155649

Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.

G A Caballero, R K Ausman, E J Quebbeman.   

Abstract

Twenty-three patients with metastatic adenocarcinomas were treated with long-term, continuous, ambulatory iv infusion of 5-FU. Length of infusion ranged from 54 to 324 days. The usual daily dose was 300 mg/m2. Toxicity was primarily stomatitis. Hand/foot syndrome occurred in 11 patients. Nausea, vomiting, myelosuppression, and alopecia were not observed. Thirteen patients had stomatitis. Eighteen patients had evaluable lesions; eight achieved partial response, five had stable disease, and five had progressive disease. Further studies are necessary to confirm the level of tumor response and survival period of patients treated with this method.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155649

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  17 in total

1.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.

Authors:  C J Fabian; R Molina; M Slavik; S Dahlberg; S Giri; R Stephens
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Phase I trial of 5-fluorouracil by 24-hour infusion weekly.

Authors:  N B Haas; J B Hines; G R Hudes; N Johnston; R F Ozols; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

3.  Salivary passage of 5-fluorouracil during continuous infusion.

Authors:  G Milano; A Thyss; J Santini; M Frenay; E Francois; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Effects of carp and tuna oils on 5-fluorouracil-induced antitumor activity and side effects in sarcoma 180-bearing mice.

Authors:  Y Kimura; T Takaku; S Nakajima; H Okuda
Journal:  Lipids       Date:  2001-04       Impact factor: 1.880

5.  Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors:  S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Hepatoprotective Activity of Gentisic Acid on 5-Fluorouracil-induced Hepatotoxicity in Wistar Rats

Authors:  Rohini Revansiddappa Pujari; Deepti Dinesh Bandawane
Journal:  Turk J Pharm Sci       Date:  2021-06-18

7.  A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.

Authors:  Yutaka Kimura; Nobuteru Kikkawa; Shohei Iijima; Takeshi Kato; Yasuto Naoi; Taro Hayashi; Takahiko Tanigawa; Hitoshi Yamamoto; Eiji Kurokawa
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

8.  Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators.

Authors:  Ana Paula F Freitas; Flavio S Bitencourt; Gerly Anne C Brito; Nylane Maria N de Alencar; Ronaldo A Ribeiro; Roberto Cesar P Lima-Júnior; Marcio V Ramos; Mariana L Vale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-14       Impact factor: 3.000

9.  Evaluation of in-vitro cytotoxic effect of 5-FU loaded-chitosan nanoparticles against spheroid models.

Authors:  Taylor Smith; Kevin Affram; Errol Bulumko; Edward Agyare
Journal:  J Nat Sci       Date:  2018-10

Review 10.  Continuous 5-fluorouracil in the treatment of breast cancer.

Authors:  D A Cameron; H Gabra; R C Leonard
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.